Future oncology最新文献_第7页

Tumor budding and Ki-67 proliferation index as biomarkers for NAC response and prognosis in breast cancer. 肿瘤出芽和Ki-67增殖指数作为乳腺癌NAC反应和预后的生物标志物。

IF 2.6 4区医学

Future oncology Pub Date : 2025-09-01 Epub Date: 2025-08-14 DOI: 10.1080/14796694.2025.2547407

Oğuzhan Okcu, Çiğdem Öztürk, Bayram Şen

{"title":"Tumor budding and Ki-67 proliferation index as biomarkers for NAC response and prognosis in breast cancer.","authors":"Oğuzhan Okcu, Çiğdem Öztürk, Bayram Şen","doi":"10.1080/14796694.2025.2547407","DOIUrl":"10.1080/14796694.2025.2547407","url":null,"abstract":"Aims: Neoadjuvant chemotherapy (NAC) enhances the possibility of breast conserving surgery and improves survival in patients with complete response in breast carcinoma. The most crucial step for maximum benefit and minimum damage in neoadjuvant chemotherapy is selecting the most eligible patient.Materials & methods: The study included 191 patients diagnosed with invasive breast carcinoma of no special type in needle biopsy samples. The effect of tumor budding (TB) and the Ki-67 proliferation index on NAC response and survival were assessed.Results: Tumor budding was associated with metastasis (p < 0.001), survival (p = 0.002), and molecular subtype (p = 0.045). In multivariate analysis, TB was an independent risk factor for disease free survival (DFS). There was no significant correlation between NAC response and TB (p = 0.104). The cutoff value of the Ki-67 proliferation index in response to NAC was determined as 19%.Conclusion: Neoadjuvant chemotherapy response is observed more positively in tumors with KI-67 index of 19% and above. Although intratumoral TB is not detected in correlation with NAC response, it has an independent effect on DFS. Adding TB parameter to the pathology report format of needle biopsy materials has the potential to make a positive contribution to patient management.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2885-2893"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439553/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144855009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical outcome and influencing factors of differentiated thyroid cancer with biochemical incomplete response. 分化型甲状腺癌生化反应不完全的临床结局及影响因素分析。

IF 2.6 4区医学

Future oncology Pub Date : 2025-09-01 Epub Date: 2025-08-20 DOI: 10.1080/14796694.2025.2548161

Congcong Wang, Guohua Qin, Shuhui Wang, Yutian Li, Yaqi Lu, Xia Shen, Wei Sun, Jiao Li, Na Han, Chenghui Lu, Guoqiang Wang, Yingying Zhang, ZengHua Wang, Zengmei Si, Fengqi Li, Xufu Wang, Yansong Lin, Xinfeng Liu

{"title":"Clinical outcome and influencing factors of differentiated thyroid cancer with biochemical incomplete response.","authors":"Congcong Wang, Guohua Qin, Shuhui Wang, Yutian Li, Yaqi Lu, Xia Shen, Wei Sun, Jiao Li, Na Han, Chenghui Lu, Guoqiang Wang, Yingying Zhang, ZengHua Wang, Zengmei Si, Fengqi Li, Xufu Wang, Yansong Lin, Xinfeng Liu","doi":"10.1080/14796694.2025.2548161","DOIUrl":"10.1080/14796694.2025.2548161","url":null,"abstract":"Purpose: The aim of our study was to investigate the clinical outcomes and predictive factors in patients with biochemical incomplete response (BIR) after initial radioiodine therapy (RAI).Materials & methods: This retrospective study enrolled 198 patients with BIR from two institutions and stratified them into a training cohort (Qingdao cohort, n = 144) and an external validation cohort (Beijing cohort, n = 54). The patients were classified as having incomplete response (IR) or non-IR disease at the final follow-up. Univariate and multivariate analyses identified IR predictors in the training cohort. A nomogram was developed using the training cohort and was validated in the validation cohort using calibration curves, decision curve analysis (DCA), and receiver operating characteristic analysis.Results: Age, recurrence risk, pre-stimulated thyroglobulin (ps-Tg), and BRAFV600E mutation were independent predictors of IR in the training cohort. The nomogram identified ps-Tg as the strongest predictor of IR risk, followed by the BRAFV600E mutation, age, and recurrence risk. The calibration curves demonstrated excellent agreement between the predicted and observed probabilities. DCA confirmed favorable clinical utility.Conclusions: This validated nomogram provides a clinically useful tool for quantifying IR risk in BIR patients, supporting personalized management decisions after initial RAI.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2911-2919"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439549/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhancing short-term recovery after gastric cancer surgery: an information-motivation-behavioral skills (IMB) model with nutritional support. 促进胃癌术后短期恢复：营养支持下的信息-动机-行为技能（IMB）模型。

IF 2.6 4区医学

Future oncology Pub Date : 2025-09-01 Epub Date: 2025-08-05 DOI: 10.1080/14796694.2025.2543231

Gang Wang, Shengjie Pan

{"title":"Enhancing short-term recovery after gastric cancer surgery: an information-motivation-behavioral skills (IMB) model with nutritional support.","authors":"Gang Wang, Shengjie Pan","doi":"10.1080/14796694.2025.2543231","DOIUrl":"10.1080/14796694.2025.2543231","url":null,"abstract":"Aims: To evaluate the short-term efficacy of an Information - Motivation - Behavioral Skills (IMB) model-based intervention combined with perioperative nutritional support in improving postoperative recovery in patients undergoing radical gastrectomy for gastric cancer.Materials and methods: In this randomized controlled trial, 250 gastric cancer patients were allocated to either an intervention group (IMB model + individualized nutritional support, n = 125) or a control group (standard care, n = 125). The 15-day intervention targeted key recovery dimensions: sleep quality, nutritional status, pain, psychological well-being, and quality of life (QoL).Results: Compared to controls, the intervention group showed significantly greater improvements in Pittsburgh Sleep Quality Index (PSQI) scores (-2.16 ± 0.74 vs. -1.32 ± 0.69), serum albumin levels (+5.56 ± 1.43 g/L vs. +2.03 ± 1.21 g/L), and global QoL based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30; +21.14 ± 6.91 vs. +9.04 ± 5.87; all P < 0.001). Pain (Visual Analog Scale), anxiety (Self-Rating Anxiety Scale), and depression (Self-Rating Depression Scale) scores also improved significantly.Conclusion: IMB-guided psychosocial intervention with tailored nutritional support significantly enhanced short-term recovery. Further studies are needed to validate long-term efficacy.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2775-2784"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12407642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144788880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New targets and strategies in treatment of metastatic gastric cancer. 转移性胃癌治疗的新靶点和新策略。

IF 2.6 4区医学

Future oncology Pub Date : 2025-09-01 Epub Date: 2025-08-17 DOI: 10.1080/14796694.2025.2547562

Melih Simsek, Haci Mehmet Turk

{"title":"New targets and strategies in treatment of metastatic gastric cancer.","authors":"Melih Simsek, Haci Mehmet Turk","doi":"10.1080/14796694.2025.2547562","DOIUrl":"10.1080/14796694.2025.2547562","url":null,"abstract":"Introduction: Gastric cancer is a common type of cancer and one of the leading causes of cancer-related deaths. Unfortunately, the number of cases has been rising in recent years. Since this cancer often does not show symptoms in its early stages, most people are diagnosed when the disease is already advanced (stage 3 or 4). At this stage, survival rates are low, with most patients living about 12 months on average.Treatment options: For advanced gastric cancer, the most commonly used treatments are chemotherapy combinations that include oxaliplatin and fluoropyrimidine. Another option is irinotecan, which can be used instead of oxaliplatin. However, older drugs like anthracyclines and docetaxel are no longer widely used. A newer combination of oxaliplatin, fluoropyrimidine, leucovorin, and docetaxel has fewer side effects compared to older treatments.Recent advances: In recent years, researchers have discovered new ways to target gastric cancer. These include therapies that combine antibodies with drugs, therapies that use multiple antibodies, and immunotherapies that help the immune system fight cancer. These new treatments, when added to chemotherapy, offer hope for improving survival rates in people with advanced gastric cancer.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2931-2940"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439571/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144872872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Phase 1 study of the novel GCN2 kinase activator NXP800 in patients with advanced cholangiocarcinoma. 新型GCN2激酶激活剂NXP800在晚期胆管癌患者中的一期研究

IF 2.6 4区医学

Future oncology Pub Date : 2025-09-01 Epub Date: 2025-07-28 DOI: 10.1080/14796694.2025.2539611

Hendrien Kuipers, Joseph J Larson, Caitlin B Conboy, Daniel H Ahn, Tanios Bekaii-Saab, Christina Wu, Mohamad Bassam Sonbol, Sumera I Ilyas, Gregory J Gores, Rory L Smoot, Mitesh J Borad

引用次数: 0

The benefits and pitfalls of adding bevacizumab to neoadjuvant chemotherapy for advanced ovarian cancer: a meta-analysis. 晚期卵巢癌新辅助化疗中加入贝伐单抗的益处和缺陷：一项荟萃分析。

IF 2.6 4区医学

Future oncology Pub Date : 2025-09-01 Epub Date: 2025-08-22 DOI: 10.1080/14796694.2025.2548188

Zeyi Zhao, Lei Cheng, Xin Tong, Shuai Xu, Qingqing Zhuang

{"title":"The benefits and pitfalls of adding bevacizumab to neoadjuvant chemotherapy for advanced ovarian cancer: a meta-analysis.","authors":"Zeyi Zhao, Lei Cheng, Xin Tong, Shuai Xu, Qingqing Zhuang","doi":"10.1080/14796694.2025.2548188","DOIUrl":"10.1080/14796694.2025.2548188","url":null,"abstract":"Objective: To appraise the efficacy and toxicity of adding bevacizumab to neoadjuvant chemotherapy (NACT) for advanced-stage ovarian cancer (AOC).Method: All studies regarding neoadjuvant bevacizumab for AOC published in PubMed, EMBASE, Scopus and Web of Science from 1 November 2010 to 31 December 2024 were retrieved and reviewed.Results: Three randomized clinical trials, five retrospective cohort studies, and six case series were eligible, including 687 patients receiving bevacizumab-NACT and 1482 patients receiving standard-NACT. There were no significant differences between the bevacizumab-NACT group and the standard-NACT group in the rates of interval debulking surgery implementation, achieving complete cytoreduction, wound complication, thrombogenesis, and infections (grade ≥3). The rate of achieving optimal cytoreduction in bevacizumab-NACT group was significantly higher than that in standard-NACT group (RR: 1.17, 95% CI: 1.02 to 1.34, P = 0.02; I2 = 30%). However, the bevacizumab-NACT group exhibited an increased risk of gastrointestinal perforation (RR: 6.97, 95% CI: 1.28 to 37.99, P = 0.02; I2 = 0%), with an incidence of 1.2% (95% CI: 0% to 3.6%; I2 = 34%).Conclusion: Adding bevacizumab to NACT for AOC can enhance the feasibility of optimal cytoreduction, rather than complete cytoreduction. However, bevacizumab-NACT increased the risk of gastrointestinal perforation.Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD42024566484.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2921-2929"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439575/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

State-level opportunities to advance biomarker testing in patients with advanced cancers and state-regulated plans. 推进晚期癌症患者生物标志物检测的国家级机会和国家监管计划。

IF 2.6 4区医学

Future oncology Pub Date : 2025-09-01 Epub Date: 2025-08-05 DOI: 10.1080/14796694.2025.2542114

William B Wong, Tu My To

{"title":"State-level opportunities to advance biomarker testing in patients with advanced cancers and state-regulated plans.","authors":"William B Wong, Tu My To","doi":"10.1080/14796694.2025.2542114","DOIUrl":"10.1080/14796694.2025.2542114","url":null,"abstract":"Introduction: This study evaluated the landscape and opportunities for improved testing coverage/reimbursement in state-regulated health plans.Materials & methods: Upfront biomarker testing reimbursements (multigene panel testing [MGPT]/single gene testing/no testing; ≤ 90 days after advanced non-small cell lung cancer [aNSCLC] or metastatic colorectal cancer [mCRC] diagnosis) from the IQVIA PharMetrics Plus claims database were assessed by health plan (fully insured, self-funded) and state (2018-2022; via adjusted generalized linear models; bivariate state comparisons via χ2 tests).Results: Among 20,261 patients with aNSCLC (50.3%) or mCRC (49.7%), odds for claims for upfront testing and MGPT, respectively, were 10% (odds ratio [OR]: 0.90 [0.84-0.97], P < 0.01) and 44% lower (OR: 0.56 [0.51-0.62], P < 0.01) for fully insured versus self-funded plans. MGPT claims were identified for < 5% of patients in 13 states and < 10% in 41. Compared with self-funded plans, significantly lower proportions of patients with fully insured plans had upfront testing claims in 6 states (P < 0.05) and MGPT in 10 (differences: 5.7-14.3%, P < 0.05).Conclusion: Lower upfront testing and MGPT reimbursement among fully insured versus self-funded health plans suggests an opportunity for state-level legislation to improve testing coverage and access.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2747-2755"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12407994/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144788881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Community hematologist/oncologist perspectives on minimal residual disease testing in patients with multiple myeloma. 社区血液学家/肿瘤学家对多发性骨髓瘤患者微量残留疾病检测的看法

IF 2.6 4区医学

Future oncology Pub Date : 2025-09-01 Epub Date: 2025-08-20 DOI: 10.1080/14796694.2025.2546284

Lucio N Gordan, Amanda Warner, Trevor Heritage, Amy Ming, Niodita Gupta-Werner, Shuchita Kaila, Annelore Cortoos

{"title":"Community hematologist/oncologist perspectives on minimal residual disease testing in patients with multiple myeloma.","authors":"Lucio N Gordan, Amanda Warner, Trevor Heritage, Amy Ming, Niodita Gupta-Werner, Shuchita Kaila, Annelore Cortoos","doi":"10.1080/14796694.2025.2546284","DOIUrl":"10.1080/14796694.2025.2546284","url":null,"abstract":"Aim: To explore community hematologist/oncologist perspectives on the patterns, drivers, and barriers of use of minimal residual disease (MRD) testing in patients with multiple myeloma (MM), and gain understanding on the use of these test results in clinical decision-making and response-adapted treatment approaches.Methods: A survey was conducted among hematologists/oncologists from a large community oncology practice network in the US who use MRD testing in the management of patients with MM.Results: Of 22 hematologists/oncologists included, 72.7% reported being comfortable/very comfortable with MRD testing but prescribed a median of only 2.5 tests between September 2019 and October 2023. The most frequently reported driver for MRD testing was to monitor patient remission status. The logistics of sending samples to MRD testing facilities was the most frequently reported perceived barrier for MRD testing. The use of MRD test results to guide treatment decisions and further MRD monitoring varied.Conclusion: There are opportunities to reduce the barriers for the use of MRD testing and for generation of additional data on the clinical impact of these test results to support the development of guidelines and provide further education on the implementation of MRD test results in clinical practice and aid clinical decision-making.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2875-2883"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439568/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144950994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma. SGNDV-001：地西他单维多汀联合派姆单抗治疗表达her2的局部晚期或转移性尿路上皮癌

IF 2.6 4区医学

Future oncology Pub Date : 2025-09-01 Epub Date: 2025-07-29 DOI: 10.1080/14796694.2025.2535280

Thomas B Powles, Enrique Grande, Nimira Alimohamed, Niara Oliveira, Srikala S Sridhar, Alexandra Drakaki, Ravindran Kanesvaran, Yohann Loriot, Andrea Necchi, Sonia Franco, Dingfeng Jiang, Kristel Apolinario, Wei Zhang, Matthew D Galsky

{"title":"SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma.","authors":"Thomas B Powles, Enrique Grande, Nimira Alimohamed, Niara Oliveira, Srikala S Sridhar, Alexandra Drakaki, Ravindran Kanesvaran, Yohann Loriot, Andrea Necchi, Sonia Franco, Dingfeng Jiang, Kristel Apolinario, Wei Zhang, Matthew D Galsky","doi":"10.1080/14796694.2025.2535280","DOIUrl":"10.1080/14796694.2025.2535280","url":null,"abstract":"Introduction: Platinum-based chemotherapy for the treatment of locally advanced or metastatic urothelial carcinoma (la/mUC), has been the first-line standard of care for many decades. Enfortumab vedotin, an antibody-drug conjugate, combined with pembrolizumab, a programmed death 1 (PD-1) inhibitor, recently demonstrated improved efficacy versus chemotherapy in la/mUC. Since 60%-80% of patients with UC have tumors expressing human epidermal growth factor receptor 2 (HER2), HER2-directed vedotin-based antibody-drug conjugates may also be beneficial in la/mUC.Patients and methods: The phase 3 trial SGNDV-001 (C5731001; NCT05911295) is evaluating disitamab vedotin (HER2-directed antibody-drug conjugate) with pembrolizumab compared with chemotherapy in treatment-naive patients with HER2-expressing la/mUC. Dual primary endpoints are progression-free survival (per blinded independent central review) and overall survival. Potential synergistic effects of disitamab vedotin and pembrolizumab could establish this combination as a novel therapeutic option for HER2-expressing la/mUC.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2705-2712"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12407659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144729679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patterns of treatment in first and subsequent lines in RCC in Spain. A real-world descriptive cross-sectional study. 西班牙RCC一线及后续治疗模式。一个真实世界的描述性横断面研究。

IF 2.6 4区医学

Future oncology Pub Date : 2025-09-01 Epub Date: 2025-08-07 DOI: 10.1080/14796694.2025.2542030

José A Arranz, Cristina Martínez, Lucía Gallego, Ana Heredero, Pablo Rebollo, Laura Fernández, Elvira Estella, David Vilanova Larena, Virginia Palomar

{"title":"Patterns of treatment in first and subsequent lines in RCC in Spain. A real-world descriptive cross-sectional study.","authors":"José A Arranz, Cristina Martínez, Lucía Gallego, Ana Heredero, Pablo Rebollo, Laura Fernández, Elvira Estella, David Vilanova Larena, Virginia Palomar","doi":"10.1080/14796694.2025.2542030","DOIUrl":"10.1080/14796694.2025.2542030","url":null,"abstract":"Aim: Advanced renal cell carcinoma (RCC) has had limited treatment options and poor prognosis. Initially, tyrosine kinase inhibitors (TKIs) increased progression-free survival (PFS) and allowed the identification of favorable (FP), intermediate (IP) and poor prognosis (PP) subgroups. While TKIs remain an option for FP patients, combinations of immune checkpoint inhibitors (IO) plus TKI in the overall population, or IO/IO in IP/PP patients, have improved overall survival (OS), and have become the standard of care. However, their adoption in clinical practice varies across countries.Method: We conducted a cross-sectional observational study using Oncology Dynamics™ database to assess treatment patterns in Spain.Results: A total of 1,587 metastatic RCC (mRCC) patients were registered, 900 in first-line treatment for clear cell mRCC (mccRCC). In 2022, among mccRCC FP patients treated by oncologists (N = 137), 92.7% received TKIs; while IP/PP patients (N = 298), 56.7% received TKIs, 27.5% antiPD1-antiCTLA4, and 13.8% antiPD1-TKI. In 2023, mccRCC FP patients (N = 124) received 94.4% TKIs; and IP/PP patients (N = 256) received 48.4% TKIs, 38.3% antiPD1-antiCTLA4, and 12.1% antiPD1-TKI.Conclusions: During this period, the uptake of IO/IO and IO/TKI in clinical practice in Spain was lower than expected according to current recommendations.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2767-2774"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12407652/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144794215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0